StockData
Gilead Sciences, Inc. logo

Gilead Sciences, Inc.

GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.33−0.35 (-0.21%)

Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%

Gilead Sciences Vemlidy (tenofovir alafenamide by Quarter

Vemlidy (tenofovir alafenamide — HBV) — Rest of World sales ($M) ($M)

QuarterlyAnnual

Gilead Sciences Vemlidy (tenofovir alafenamide: $152M in Q2 2026, up 29.9% from a year earlier. That is the highest of the 38 quarters on record here.

Latest, Q2 2026
152
Period ended Jun 30, 2026
Change on a year earlier
+29.9%
117 in Q2 2025
History
38 quarters
Since Q1 2017
Sources
30
Documents cited below

Where the Q2 2026 figure comes from

Source: Form 10-Q (filed 2026-08-06) ↗

Reported in Form 10-Q / 10-K Disaggregated Revenue Note & Form 8-K Product Sales Summary.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedVemlidy (tenofovir alafenamide — HBV) — Rest of World sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026152+29.9%Form 10-Q (filed 2026-08-06) ↗
Q1 2026Mar 31, 2026132-5.7%Form 10-Q (filed 2026-05-07) ↗
Q4 2025Dec 31, 2025125+25.0%Form 10-K (filed 2026-02-24) ↗
Q3 2025Sep 30, 2025132+38.9%Form 10-Q (filed 2025-11-07) ↗
Q2 2025Jun 30, 2025117+1.7%Form 10-Q (filed 2026-08-06) ↗
Q1 2025Mar 31, 2025140+17.6%Form 10-Q (filed 2026-05-07) ↗
Q4 2024Dec 31, 2024100+8.7%Form 10-K (filed 2026-02-24) ↗
Q3 2024Sep 30, 202495-10.4%Form 10-Q (filed 2025-11-07) ↗
Q2 2024Jun 30, 2024115+1.8%Form 10-Q (filed 2025-08-07) ↗
Q1 2024Mar 31, 2024119+15.5%Form 10-Q (filed 2025-05-07) ↗
Q4 2023Dec 31, 202392+2.2%Form 10-K (filed 2026-02-24) ↗
Q3 2023Sep 30, 2023106+17.8%Form 10-Q (filed 2024-11-12) ↗
Q2 2023Jun 30, 2023113+27.0%Form 10-Q (filed 2024-08-08) ↗
Q1 2023Mar 31, 2023103-7.2%Form 10-Q (filed 2024-05-08) ↗
Q4 2022Dec 31, 202290-8.2%Form 10-K (filed 2025-02-28) ↗
Q3 2022Sep 30, 202290-6.2%Form 10-Q (filed 2023-11-07) ↗

Cite this data

StockData. (2026). Gilead Sciences Vemlidy (tenofovir alafenamide ($M), quarterly Q1 2017–Q2 2026 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/liver-vemlidy-row

See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.